Prof. Sandrine Faivre, M.D., Ph.D.

Prof. Sandrine Faivre, M.D., Ph.D.

Overview

Professor of Medical Oncology at the University Paris VII (Denis Diderot), Clinical and Translational Research, at Hôpitaux Universitaires Saint-Louis Lariboisière Fernand Widal, Assistance Publique-Hôpitaux de Paris. She is MD & PhD, working on signaling involved in tumor proliferation, invasion, angiogenesis, and microenvironment to generate scientific rationale for innovative cancer targets. She has been investigator of more than 100 phase I/II studies, published first-in- man phase I trials of sunitinib, temsirolimus, everolimus, and investigates molecular biomarkers of sensitivity/resistance to targeted agents including immunotherapy. In addition to gastrointestinal oncology, head & neck oncology, she focuses on phase I/II trials including molecular pharmacology and translational research using VEGFR-multikinase inhibitors, FGFR inhibitors, TGFbeta and PD-1/PD-L1 inhibitors among others. She is a member of the ILCA, AACR, ASCO, ESMO. She has published more than 180 peer-reviewed papers.

Paris, France
French / English

Work Experience

Professor of Medical Oncology
University Paris VII (Denis Diderot)
Clinical and Translational Research Assistance Publique-Hôpitaux de Paris
Hôpitaux Universitaires Saint-Louis Lariboisière Fernand Widal

Pubmed

Selective Oral MEK1/2 Inhibitor Pimasertib in Metastatic Melanoma: Antitumor Activity in a Phase I, Dose-Escalation Trial.
2020
Targeted oncology Read it here Septic shock caused by <i>Gardnerella vaginalis</i> and <i>Atopobium vaginae</i>.
2020
IDCases Read it here Impact of the COVID-19 Outbreak on the Management of Patients with Cancer.
2020
Targeted oncology Read it here

Professional Associations

ILCA (International Liver Cancer Association) Member American Association for Cancer Research (AACR) Member American Society of Clinical Oncology (ASCO) Member